Research & Literature

Understanding autoimmunity of vitiligo and alopecia areata.

Rork JF, Rashighi M, Harris JE

Current opinion in pediatrics 2016; (28(4)):463-9 doi:10.1097/MOP.0000000000000375.

Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.

Liu LY, Craiglow BG, Dai F, King BA

Journal of the American Academy of Dermatology 2017; (76(1)):22-28 doi:10.1016/j.jaad.2016.09.007.

Polyglandular autoimmune syndrome type III with a prevalence of cutaneous features.

Capo A, Amerio P

Clinical and experimental dermatology 2017; (42(1)):61-63 doi:10.1111/ced.12984.

Excellent response to tofacitinib treatment in a patient with alopecia universalis.

Erduran F, Adışen E, Aksakal AB

Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2017; (26(2)):47-49 doi:10.15570/actaapa.2017.15.

Long-Term Prognosis of Alopecia Totalis and Alopecia Universalis: A Longitudinal Study with More than 10 Years of Follow-Up: Better than Reported.

Jang YH, Hong NS, Moon SY, et al.

Dermatology (Basel, Switzerland) 2017; (233(2-3)):250-256 doi:10.1159/000477458.

Rare Presentation of Alopecia Universalis Congenita and Twenty-nail Dystrophy in Siblings.

Mitra D, Agarwal R, Chopra A, Kandpal R

International journal of trichology 2017; (9(2)):63-66 doi:10.4103/ijt.ijt_48_17.

Nail Involvement in Alopecia Areata: A Questionnaire-based Survey on Clinical Signs, Impact on Quality of Life and Review of the Literature.

Roest YBM, van Middendorp HT, Evers AWM, et al.

Acta dermato-venereologica 2018; (98(2)):212-217 doi:10.2340/00015555-2810.

Janus kinase inhibitors for the use of alopecia areata: A promising therapeutic of the future.

Updyke KM

Dermatologic therapy 2018; (31(1)) doi:10.1111/dth.12556.

Alopecia areata: a review of disease pathogenesis.

Rajabi F, Drake LA, Senna MM, Rezaei N

The British journal of dermatology 2018; (179(5)):1033-1048 doi:10.1111/bjd.16808.

Quality of life in mild and severe alopecia areata patients.

Abedini R, Hallaji Z, Lajevardi V, et al.

International journal of women's dermatology 2018; (4(2)):91-94 doi:10.1016/j.ijwd.2017.07.001.

Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients.

Shivanna CB, Shenoy C, Priya RA

International journal of trichology 2018; (10(3)):103-107 doi:10.4103/ijt.ijt_21_18.

Living with alopecia areata: an online qualitative survey study.

Davey L, Clarke V, Jenkinson E

The British journal of dermatology 2019; (180(6)):1377-1389 doi:10.1111/bjd.17463.

Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.

Gordon SC, Abudu M, Zancanaro P, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(4)):e156-e157 doi:10.1111/jdv.15383.

The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.

Crowley EL, Fine SC, Katipunan KK, Gooderham MJ

Journal of cutaneous medicine and surgery 2019; (23(3)):289-297 doi:10.1177/1203475418824079.

Suspected Herpes Zoster-associated Encephalitis during Treatment with Oral Tofacitinib in Alopecia Universalis.

Hosking AM, Juhász M, Mesinkovska NA

International journal of trichology 2018; (10(6)):286-288 doi:10.4103/ijt.ijt_87_18.

Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity.

Bain KA, McDonald E, Moffat F, et al.

The British journal of dermatology 2020; (182(1)):130-137 doi:10.1111/bjd.18008.

A cross-sectional study of the histopathology and immunology of alopecia areata: Unearthing the role of the Janus kinase-signal transducer and activator of transcription pathway.

Bansal A, Relhan V, Garg VK, Saran RK

Indian journal of dermatology, venereology and leprology 2019; (85(5)):455-461 doi:10.4103/ijdvl.IJDVL_738_17.

The relationship between physical activity levels and symptoms of depression, anxiety and stress in individuals with alopecia Areata.

Rajoo Y, Wong J, Cooper G, et al.

BMC psychology 2019; (7(1)):48 doi:10.1186/s40359-019-0324-x.

Vitamin D and alopecia areata: possible roles in pathogenesis and potential implications for therapy.

Lin X, Meng X, Song Z

American journal of translational research 2019; (11(9)):5285-5300.

An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature.

Berbert Ferreira R, Ferreira SB, Scheinberg MA

Clinical case reports 2019; (7(12)):2539-2542 doi:10.1002/ccr3.2484.

Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata.

Wyrwich KW, Kitchen H, Knight S, et al.

American journal of clinical dermatology 2020; (21(5)):725-732 doi:10.1007/s40257-020-00545-9.

Immunology of alopecia areata.

Żeberkiewicz M, Rudnicka L, Malejczyk J

Central-European journal of immunology 2020; (45(3)):325-333 doi:10.5114/ceji.2020.101264.

Multiple Autoimmune Syndrome With Alopecia Universalis and Immune Thrombocytopenic Purpura.

Alwasaidi TA, Mustafa W, Osman H, et al.

Cureus 2021; (13(1)):e13033 doi:10.7759/cureus.13033.

Microblading and the Science Behind it.

Marwah MK, Kerure AS, Marwah GS

Indian dermatology online journal 2021; (12(1)):6-11 doi:10.4103/idoj.IDOJ_230_20.

Metabolic syndrome in patients with Alopecia Areata: A case-control study.

Abdollahimajd F, Niknezhad N, Bahreini N, et al.

Dermatologic therapy 2021; (34(4)):e14979 doi:10.1111/dth.14979.

Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors.

Zheng C, Tosti A

Dermatologic clinics 2021; (39(3)):407-415 doi:10.1016/j.det.2021.03.005.

Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.

Yu DA, Kim YE, Kwon O, Park H

Indian journal of dermatology, venereology and leprology 2021; (87(5)):621-627.

Alopecias in humans: biology, pathomechanisms and emerging therapies.

Willems A, Sinclair R

Veterinary dermatology 2021; (32(6)):596-e159 doi:10.1111/vde.13014.

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.

Qi F, Liu F, Gao L

Frontiers in immunology 2021; (12()):790125 doi:10.3389/fimmu.2021.790125.

Alopecia Universalis Associated with Hyperthyroidism Treated with Azathioprine and Hydroxychloroquine: A Case Report.

Paudel V, Chudal D, Pradhan MB, et al.

JNMA; journal of the Nepal Medical Association 2021; (59(241)):935-937 doi:10.31729/jnma.5830.

Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.

Ramírez-Marín HA, Tosti A

Drug design, development and therapy 2022; (16()):363-374 doi:10.2147/DDDT.S334727.

Topical bimatoprost in the treatment of eyelash loss in alopecia totalis and universalis: A prospective, open-label study.

Ricar J, Cetkovska P, Hordinsky M, Ricarova R

Dermatologic therapy 2022; (35(6)):e15438 doi:10.1111/dth.15438.

Two Phase 3 Trials of Baricitinib for Alopecia Areata.

King B, Ohyama M, Kwon O, et al.

The New England journal of medicine 2022; (386(18)):1687-1699 doi:10.1056/NEJMoa2110343.

Patient and physician perspectives on alopecia areata: A real-world assessment of severity and burden in Japan.

Edson-Heredia E, Aranishi T, Isaka Y, et al.

The Journal of dermatology 2022; (49(6)):575-583 doi:10.1111/1346-8138.16360.

Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study.

Waśkiel-Burnat A, Kotowska M, Dorobek W, et al.

Clinical and experimental dermatology 2022; (47(8)):1517-1522 doi:10.1111/ced.15206.

Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.

Renert-Yuval Y, Correa da Rosa J, Garcet S, et al.

The British journal of dermatology 2022; (187(4)):539-547 doi:10.1111/bjd.21696.

Autoantigen Discovery in the Hair Loss Disorder, Alopecia Areata: Implication of Post-Translational Modifications.

Jadeja SD, Tobin DJ

Frontiers in immunology 2022; (13()):890027 doi:10.3389/fimmu.2022.890027.

Alopecia areata: descriptive analysis in a Brazilian sample.

Lopes ASA, Santos LDN, Razé MC, Lazzarini R

Anais brasileiros de dermatologia 2022; (97(5)):654-656 doi:10.1016/j.abd.2021.04.016.

Acquired causes of eyebrow and eyelash loss: A review and approach to diagnosis and treatment.

Mumford BP, Eisman S, Yip L

The Australasian journal of dermatology 2023; (64(1)):28-40 doi:10.1111/ajd.13947.

Baricitinib as the first systemic treatment for severe alopecia areata.

Kincaid CM, Arnold JD, Mesinkovska NA

Expert review of clinical immunology 2023; (19(6)):565-573 doi:10.1080/1744666X.2023.2200166.

Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.

Papierzewska M, Waśkiel-Burnat A, Rudnicka L

Clinical drug investigation 2023; (43(5)):325-334 doi:10.1007/s40261-023-01260-z.

Impact and Management of Loss of Eyebrows and Eyelashes.

Starace M, Cedirian S, Alessandrini AM, et al.

Dermatology and therapy 2023; (13(6)):1243-1253 doi:10.1007/s13555-023-00925-z.

Ritlecitinib: First Approval.

Blair HA

Drugs 2023; (83(14)):1315-1321 doi:10.1007/s40265-023-01928-y.

Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis.

Xu Q, He L, Yin Y

Frontiers in pharmacology 2023; (14()):1241954 doi:10.3389/fphar.2023.1241954.

Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study.

Thaçi D, Tziotzios C, Ito T, et al.

Dermatology and therapy 2023; (13(11)):2621-2634 doi:10.1007/s13555-023-00997-x.

Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.

De Greef A, Thirion R, Ghislain PD, Baeck M

Dermatology and therapy 2023; (13(11)):2869-2877 doi:10.1007/s13555-023-01030-x.

Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study.

Huang J, Tan Z, Tang Y, Shi W

Frontiers in medicine 2023; (10()):1287139 doi:10.3389/fmed.2023.1287139.

Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.

Huang J, Qian P, Tang Y, et al.

Acta dermato-venereologica 2023; (103()):adv12425 doi:10.2340/actadv.v103.12425.

European expert consensus statement on the systemic treatment of alopecia areata.

Rudnicka L, Arenbergerova M, Grimalt R, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2024; (38(4)):687-694 doi:10.1111/jdv.19768.

Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences.

Yamaguchi HL, Yamaguchi Y, Peeva E

International journal of molecular sciences 2024; (25(8)) doi:10.3390/ijms25084409.

Eyelash Loss: An Unusual Manifestation of Uncontrolled Hypothyroidism.

Palacios-Bayona KL, Tobón-Ospina C

Cureus 2024; (16(5)):e59551 doi:10.7759/cureus.59551.

Eyebrow and Eyelash Loss in Patients With Cancer.

Rose L, Khuhro A, Minta A, et al.

Journal of drugs in dermatology : JDD 2024; (23(5)):327-331 doi:10.36849/JDD.8003.

Exploring Janus kinase inhibitors for alopecia areata: a comprehensive review.

Bushwereb R, Srivastava G

Italian journal of dermatology and venereology 2024; (159(4)):380-389 doi:10.23736/S2784-8671.24.07894-0.

Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial.

King B, Ko J, Kwon O, et al.

JAMA dermatology 2024; (160(10)):1075-1081 doi:10.1001/jamadermatol.2024.2734.

Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis.

Mesinkovska N, King B, Zhang X, et al.

The Journal of dermatology 2024; (51(11)):1414-1424 doi:10.1111/1346-8138.17442.

Psychosocial impact of alopecia areata in paediatric and adolescent populations: A systematic review.

Tan IJ, Jafferany M

Journal of paediatrics and child health 2024; (60(12)):778-782 doi:10.1111/jpc.16678.

A Case of Idiopathic Twenty-Nail Dystrophy.

Kumar R, Mujibur Rahman A, Umapathy N, et al.

Cureus 2024; (16(9)):e70037 doi:10.7759/cureus.70037.

Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report.

Mahyad M, Baghaei M, Baghaei A, Nahayati M

International journal of rheumatic diseases 2024; (27(12)):e70028 doi:10.1111/1756-185X.70028.

Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study.

Aldebei A, Hammouri YS, Abdallat SA, et al.

Cureus 2025; (17(5)):e84321 doi:10.7759/cureus.84321.

Beyond hair loss: Exploring the psychiatric burden of alopecia areata in a large cohort.

Crawl-Bey A, Watts J, Cotton J, et al.

Journal of the National Medical Association 2025; (117(5)):335-340 doi:10.1016/j.jnma.2025.07.008.

Is Intralesional Methotrexate an Effective Alternative to Intralesional Triamcinolone in Alopecia Areata? Findings From a Randomized Controlled Trial.

Ghandi N, Rashidi A, Saberi F, et al.

Journal of cosmetic dermatology 2025; (24(8)):e70367 doi:10.1111/jocd.70367.

Association between alopecia areata and cardiovascular disease: a systematic review and meta-analysis.

Lu J, Cao X, Feng Y, et al.

Frontiers in immunology 2025; (16()):1643709 doi:10.3389/fimmu.2025.1643709.

Comparison of Current International Guidelines for the Management of Alopecia Areata-Comprehensive Review.

Kropidłowska J, Kvinen A, Lewandowski M, et al.

International journal of molecular sciences 2025; (26(17)) doi:10.3390/ijms26178632.

Efficacy of latanoprost in the treatment of ciliary madarosis.

Ksouri SE, Mahjoub A, Ben Abderrazek A, et al.

Journal francais d'ophtalmologie 2025; (48(10)):104573 doi:10.1016/j.jfo.2025.104573.

[Efficacy and safety of baricitinib treatment in alopecia areata: a retrospective analysis].

Rózsa P, Szász Z, Asztalos L, et al.

Orvosi hetilap 2025; (166(49)):1943-1948 doi:10.1556/650.2025.33444.

Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors.

Sahin G, Aydin F, Pancar Yuksel E

Journal of clinical medicine 2026; (15(1)) doi:10.3390/jcm15010396.

Developing recommendations for promoting wellbeing in individuals with alopecia areata: a modified Delphi study.

Zucchelli F, Montgomery K

BMJ open 2026; (16(2)):e094491 doi:10.1136/bmjopen-2024-094491.